Table 6.
SA‐5: Patient characteristics of the PS‐matched subgroup (included three additional potential covariates)
| IGRT (n = 191) | non‐IGRT (n = 191) | Standardized difference (rounded)* | ||||
|---|---|---|---|---|---|---|
| Number or mean (sd)§ | (%) § | Number or mean (sd)§ | (%) § | |||
| Age | <65 | 94 | (49) | 96 | (50) | 0.02 |
| ≥65 | 97 | (51) | 95 | (50) | ||
| Gender | Female | 45 | (24) | 46 | (24) | 0.01 |
| Male | 146 | (76) | 145 | (76) | ||
| Residency | Non‐north | 127 | (66) | 121 | (63) | 0.07 |
| North | 64 | (34) | 70 | (37) | ||
| Social economic status | No more than minimum wage | 50 | (26) | 48 | (25) | 0.02 |
| Higher | 141 | (74) | 143 | (75) | ||
| Comorbidity | Without | 103 | (54) | 107 | (56) | 0.04 |
| With † | 88 | (46) | 84 | (44) | ||
| Clinical stage | 3A | 56 | (29) | 49 | (26) | 0.08 |
| 3B | 135 | (71) | 142 | (74) | ||
| Histology | NSCLC | 154 | (80) | 154 | (80) | 0 |
| SCLC | 37 | (20) | 37 | (20) | ||
| Tumor location | Lower | 48 | (25) | 46 | (24) | 0.02 |
| Upper/middle | 143 | (75) | 145 | (76) | ||
| RT delivery | 3DCRT | ‡ | ‡ | ‡ | ‡ | 0.05 |
| IMRT | ‡ | ‡ | ‡ | ‡ | ||
| Peri‐CCRT Systemic therapy | Without | 109 | (57) | 112 | (59) | 0.03 |
| With | 82 | (43) | 79 | (41) | ||
| RT break | ≤1 week | 139 | (73) | 142 | (74) | 0.04 |
| >1 week | 52 | (27) | 49 | (26) | ||
| RT dose | 62.01 (6.12) | 62.03 (5.71) | 0.004 | |||
| BMI | 23.58 (3.84) | 23.34 (3.68) | 0.07 | |||
| Drinking | No | 125 | (65) | 129 | (68) | 0.04 |
| Yes | 66 | (35) | 62 | (32) | ||
| Betel nut chewing | No | 158 | (83) | 164 | (86) | 0.09 |
| Yes | 33 | (17) | 27 | (14) | ||
| Smoking | No | 57 | (30) | 58 | (30) | 0.01 |
| Yes | 134 | (70) | 133 | (70) | ||
| Performance status | 0–1 | 178 | (93) | 181 | (95) | 0.07 |
| 2 | 13 | (7) | 10 | (5) | ||
| Use of PET | No | 106 | (56) | 106 | (56) | 0 |
| Yes | 85 | (44) | 85 | (44) | ||
| Tumor size (mm) | 56.23 (24.41) | 56.34 (25.43) | 0.005 | |||
| c‐T stage | T1‐2 | 50 | (26) | 54 | (28) | 0.05 |
| T3‐4 | 141 | (74) | 137 | (72) | ||
| c‐N stage | N0‐1 | 19 | (10) | 15 | (8) | 0.07 |
| N2‐3 | 172 | (90) | 176 | (92) | ||
| Treatment era | Early | 76 | (40) | 80 | (42) | 0.04 |
| Late | 115 | (60) | 111 | (58) | ||
3DCRT, 3D conformal radiotherapy; BMI, body mass index; CCRT, concurrent chemoradiotherapy; IGRT, image‐guided radiotherapy; IMRT, intensity‐modulated radiotherapy; NSCLC, non‐small cell lung cancer; PET, positron emission tomography; PSW, propensity‐score weighting; RT, radiotherapy; SCLC, small cell lung cancer; sd, standard deviation.
†
Modified Carlson comorbidity score ≥ 1.
‡
The exact numbers were not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers in single cells (≤2).
§
Rounded.